Foot-and-mouth disease vaccine

Patent metadata

Field	Value
Publication number	US-11865171-B2
Application number	US-202117180223-A
Country	US
Kind code	B2
Filing date	Feb 19, 2021
Priority date	Jan 16, 2015
Publication date	Jan 9, 2024
Grant date	Jan 9, 2024

Abstract

Compositions for prevention of Foot and Mouth Disease (FMD) are provided, comprising an antigen component in the amount equivalent to 0.5-20 μg FMD virus and an adjuvant component comprising oil, an immunostimulatory oligonucleotide, and a polycationic carrier. Methods of using the composition, as well as the methods of reducing FMD persistence are also provided.

First claim

The invention claimed is:

1. A method of herd management, comprising administering to each member in said herd an immunogenic composition wherein said immunogenic composition comprises: a) antigen component comprising between 6 and 20 μg of FMD (Foot-and-Mouth Disease) virus per dose; b) an emulsion containing an oil; c) 75-200 μg of a CpG-containing immunostimulatory oligonucleotide per dose; d) 75-200 mg of a polycationic carrier per dose, and wherein further, upon suspected contact with FMD infection, the vaccinated members of said herd are not slaughtered.

2. A method of herd management, comprising administering to each member in said herd an immunogenic composition wherein said immunogenic composition comprises: a) antigen component comprising between 6 and 20 μg of FMD (Foot-and-Mouth Disease) virus per dose; b) an emulsion containing an oil; c) 75-200 μg of a CpG-containing immunostimulatory oligonucleotide per dose; d) 75-200 mg of a polycationic carrier per dose, and wherein further, upon suspected contact with FMD infection, the vaccinated members of said herd are quarantined for 0-30 days.

3. A method of herd management, comprising administering to each member in said herd an immunogenic composition wherein said immunogenic composition comprises: a) antigen component comprising between 6 and 20 μg of FMD (Foot-and-Mouth Disease) virus per dose; b) an emulsion containing an oil; c) 75-200 μg of a CpG-containing immunostimulatory oligonucleotide per dose; d) 75-200 mg of a polycationic carrier per dose, and wherein further, upon suspected contact with FMD infection, the vaccinated members of said herd are moved beyond the infected premises.

4. The method according to claim 1 , wherein the vaccinated members of the herd are not slaughtered and are quarantined for 0-30 days.

5. The method of any one of claims 1 - 4 , wherein said immunogenic composition comprises 6-18 μg of FMD (Foot-and-Mouth Disease) virus per dose.

6. The method of any one of claims 1 - 4 , wherein said immunogenic composition comprises 6-12 μg of FMD (Foot-and-Mouth Disease) virus per dose.

7. The method of any one of claims 1 - 4 , wherein said immunogenic composition comprises 8-12 μg of FMD (Foot-and-Mouth Disease) virus per dose.

8. The method according to any one of claims 1 - 4 , wherein the polycationic polymer is diethylaminoethyl (DEAE) Dextran.

9. The method of claim 8 , wherein said immunogenic composition comprises 6-18 μg of FMD (Foot-and-Mouth Disease) virus per dose.

10. The method of claim 8 , wherein said immunogenic composition comprises 6-12 μg of FMD (Foot-and-Mouth Disease) virus per dose.

11. The method of claim 8 , wherein said immunogenic composition comprises 8-12 μg of FMD (Foot-and-Mouth Disease) virus per dose.

12. The method according to claim 8 , wherein the immunostimulatory oligonucleotide comprises CpG.

13. The method according to claim 12 , wherein the immunostimulatory oligonucleotide comprises at least 15 contiguous nucleotides of SEQ ID NO: 8.

14. The method according to any one of claims 1 - 4 , wherein the oil is a light mineral oil.

15. The method according to claim 14 , wherein oily phase comprises 50.01%-55% v/v of the immunogenic composition.

16. The method according to claim 14 , wherein the polycationic polymer is diethylaminoethyl (DEAE) Dextran.

17. The method according to claim 16 , wherein the immunostimulatory oligonucleotide comprises CpG.

18. The method according to claim 17 , wherein the immunostimulatory oligonucleotide comprises at least 15 contiguous nucleotides of SEQ ID NO: 8.

19. The method of claim 17 , wherein said immunogenic composition comprises 6-18 μg of FMD (Foot-and-Mouth Disease) virus per dose.

20. The method of claim 17 , wherein said immunogenic composition comprises 6-12 μg of FMD (Foot-and-Mouth Disease) virus per dose.

21. The method of claim 17 , wherein said immunogenic composition comprises 8-12 μg of FMD (Foot-and-Mouth Disease) virus per dose.

Assignees

• Zoetis Services Llc
• Us Secretary Of Agriculture

Inventors

• Dominowski Paul Joseph
• Hardham John Morgan
• Jackson James Alan
• Gay Cyril Gerard
• Rodriguez Luis Leandro
• Krug Peter William
• Rieder Aida Elizabeth

Classifications

• A61K39/135 Primary

  Foot- and mouth-disease virus · CPC title

• A61K39/12 Primary

  Viral antigens · CPC title

• A61K39/39

  characterised by the immunostimulating additives, e.g. chemical adjuvants · CPC title

• A61K2039/5252

  inactivated (killed) · CPC title

• A61K2039/552

  Veterinary vaccine · CPC title